Last Price$718.2(3.6%)
Market Cap$77.0B
Dividend Yield LTM
0.0%
5Y avg
0.2%
Biotechnology industry
median
0.0%
Stock quality & Intrinsic value
6/10
0.5% undervalued
Regeneron Pharmaceuticals, Inc. Dividend Yield LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield LTM | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.3% | 1.1% | 0.8% | 0.7% | 0.6% | 0.0% | 0.0% | 0.9% | 0.0% | 0.0% | 0.0% |
Overvalued or undervalued?
Check the intrinsic value for REGN
and see if it's the right time to invest.
Regeneron Pharmaceuticals, Inc. (REGN) Dividend Yield LTM comparison analysis
General
LTM Dividend Yield LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Regeneron Pharmaceuticals, Inc.REGN
0.0%
8.3%
10.4%
31.1%
Median Peer Set
0.0%
16.4%
(41.2%)
0.4%
Royalty Pharma plcRPRX
2.6%
(3.8%)
(43.7%)
37.9%
argenx SEARGX
0.0%
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.0%
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
0.0%
18.0%
139.3%
15.0%
BioNTech SEBNTX
0.0%
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
0.0%
14.8%
(94.0%)
0.8%
Summit Therapeutics Inc.SMMT
0.0%
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
0.0%
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
0.0%
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
0.0%
23.0%
(38.6%)
(12.4%)
REGN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 66.2 (62.0%) | 63.4 (4.1%) | 125.0 97.1% | 238.5 90.7% | 379.3 59.1% | 459.1 21.0% | 445.8 (2.9%) | 1,378.5 209.2% | 2,104.7 52.7% | 2,819.6 34.0% | 4,103.7 45.5% | 4,860.4 18.4% | 5,872.2 20.8% | 6,710.8 14.3% | 7,863.4 17.2% | 8,497.1 8.1% | 16,071.7 89.1% | 12,172.9 (24.3%) | 13,117.2 7.8% | 14,202.0 8.3% |
| Cost of Goods Sold (COGS) | 9.6 | 8.1 | 0.0 | 0.9 | 1.7 | 2.1 | 4.2 | 84.5 | 155.4 | 205.0 | 392.7 | 299.7 | 397.1 | 434.1 | 782.2 | 1,119.9 | 2,437.5 | 1,560.4 | 1,815.8 | 1,970.5 |
% margin | 56.6 85.6% | 55.3 87.2% | 125.0 100.0% | 237.5 99.6% | 377.6 99.6% | 457.0 99.5% | 441.6 99.1% | 1,294.0 93.9% | 1,949.4 92.6% | 2,614.5 92.7% | 3,711.0 90.4% | 4,560.7 93.8% | 5,475.2 93.2% | 6,276.7 93.5% | 7,081.2 90.1% | 7,377.2 86.8% | 13,634.2 84.8% | 10,612.5 87.2% | 11,301.4 86.2% | 12,231.5 86.1% |
| Operating Expenses | (67.8) | 163.0 | 239.5 | 327.4 | 451.7 | 554.5 | 646.8 | 836.3 | 1,189.4 | 1,776.1 | 2,459.1 | 3,230.0 | 3,395.6 | 3,742.3 | 4,871.4 | 3,800.6 | 4,687.4 | 5,618.5 | 7,254.3 | 8,240.8 |
| Research & Development Expenses (R&D) | 155.6 | 137.1 | 201.6 | 278.0 | 398.8 | 489.3 | 529.5 | 625.6 | 859.9 | 1,271.4 | 1,620.6 | 2,052.3 | 2,075.1 | 2,186.1 | 3,036.6 | 2,735.0 | 2,908.1 | 3,592.5 | 4,439.0 | 5,132.0 |
| Selling, General & Administrative Expenses (SG&A) | 25.5 | 25.9 | 37.9 | 49.3 | 52.9 | 65.2 | 117.3 | 210.8 | 329.4 | 504.8 | 838.5 | 1,177.7 | 1,320.4 | 1,556.2 | 1,834.8 | 1,346.0 | 1,824.9 | 2,115.9 | 2,631.3 | 2,954.4 |
% margin | 124.4 188.0% | (107.7) (169.7%) | (114.5) (91.5%) | (89.8) (37.7%) | (74.1) (19.5%) | (97.5) (21.2%) | (205.2) (46.0%) | 457.7 33.2% | 760.0 36.1% | 838.4 29.7% | 1,251.9 30.5% | 1,330.7 27.4% | 2,079.6 35.4% | 2,534.4 37.8% | 2,209.8 28.1% | 3,576.6 42.1% | 8,946.8 55.7% | 4,738.9 38.9% | 4,047.1 30.9% | 3,990.7 28.1% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 30.2 | 18.5 | 45.8 | 160.1 | 495.9 | 711.4 |
| Interest Expense | 0.0 | 0.0 | 12.0 | 7.8 | 2.3 | 9.1 | 21.3 | 45.3 | 46.4 | 37.4 | 14.2 | 7.2 | 25.1 | 28.2 | 30.2 | 56.9 | 57.3 | 59.4 | 73.0 | 55.2 |
| Pre-tax Income | 124.4 | (91.1) | (93.6) | (80.4) | (72.0) | (104.5) | (222.9) | 414.4 | 713.4 | 775.7 | 1,225.1 | 1,329.8 | 2,078.5 | 2,553.5 | 2,429.1 | 3,810.4 | 9,325.8 | 4,858.8 | 4,199.3 | 4,779.9 |
% effective tax rate | 178.8 143.7% | (21.9) 24.0% | (29.8) 31.8% | 2.4 (2.9%) | (4.1) 5.7% | (2.1) 2.0% | (1.1) 0.5% | (335.8) (81.0%) | 289.0 40.5% | 427.7 55.1% | 589.0 48.1% | 434.3 32.7% | 880.0 42.3% | 109.1 4.3% | 313.3 12.9% | 297.2 7.8% | 1,250.5 13.4% | 520.4 10.7% | 245.7 5.9% | 367.3 7.7% |
% margin | (95.4) (144.2%) | (102.3) (161.3%) | (105.6) (84.5%) | (82.7) (34.7%) | (67.8) (17.9%) | (104.5) (22.8%) | (221.8) (49.7%) | 750.3 54.4% | 424.4 20.2% | 348.1 12.3% | 636.1 15.5% | 895.5 18.4% | 1,198.5 20.4% | 2,444.4 36.4% | 2,115.8 26.9% | 3,513.2 41.3% | 8,075.3 50.2% | 4,338.4 35.6% | 3,953.6 30.1% | 4,412.6 31.1% |
| EPS | (1.71) | (1.77) | (1.59) | (1.05) | (0.85) | (1.26) | (2.45) | 7.92 | 4.23 | 3.36 | 6.17 | 8.55 | 11.27 | 21.29 | 19.38 | 32.65 | 76.40 | 40.51 | 37.05 | 40.90 |
| Diluted EPS | (1.71) | (1.77) | (1.59) | (1.05) | (0.85) | (1.26) | (2.45) | 6.75 | 3.72 | 2.98 | 5.52 | 7.70 | 10.34 | 21.29 | 18.46 | 30.52 | 71.97 | 38.22 | 34.77 | 38.34 |
% margin | 139.9 211.4% | (93.1) (146.7%) | (82.1) (65.6%) | (61.3) (25.7%) | (55.4) (14.6%) | (75.7) (16.5%) | (170.5) (38.3%) | 496.7 36.0% | 784.3 37.3% | 876.6 31.1% | 1,326.8 32.3% | 1,441.7 29.7% | 2,079.6 35.4% | 2,682.6 40.0% | 2,420.1 30.8% | 3,900.5 45.9% | 9,281.0 57.7% | 5,335.4 43.8% | 4,693.3 35.8% | 5,318.0 37.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Regeneron Pharmaceuticals, Inc.'s Dividend Yield LTM?
As of today, Microsoft Corp's last 12-month Dividend Yield LTM is 0.0%, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual Dividend Yield LTM for Regeneron Pharmaceuticals, Inc. have been 0.2% over the past three years, and 0.2% over the past five years.
2) Is Regeneron Pharmaceuticals, Inc.'s Dividend Yield LTM Good?
As of today, Regeneron Pharmaceuticals, Inc.'s Dividend Yield LTM is 0.0%, which is lower than industry median of N/A. It indicates that Regeneron Pharmaceuticals, Inc.'s Dividend Yield LTM is Bad.